Several studies have reported that FLT3-ITD mutations are independent predictors of inferior overall survival in AML patients, regardless of age or cytogenetic risk group, even in the context of a normal karyotype (5, 19). This evidence concerns the gene FLT3 and acute myeloid leukemia.